Amino-Terminal Pro-B-Type Natriuretic Peptides in Stable and Unstable Ischemic Heart Disease

American Journal of Cardiology

Volumn 101, Issue 3 SUPPL., 2008, Pages

  Omland, Torbjørn ^a   de Lemos, James A ^b  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TIROFIBAN; TRANDOLAPRIL; TROPONIN;

ACUTE CORONARY SYNDROME; ARTICLE; BRAIN LEVEL; CLINICAL TRIAL; DIAGNOSTIC VALUE; DISEASE COURSE; DRUG COST; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; PLASMA; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR;

BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; HUMANS; MYOCARDIAL ISCHEMIA; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PROTEIN PRECURSORS; SEVERITY OF ILLNESS INDEX;

EID: 38649120108     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.11.025     Document Type: Article

References (23)

1. Hama N., Itoh H., Shirakami G., Nakagawa O., Suga S., Ogawa Y., Masuda I., Nakanishi K., Yoshimasa T., Hashimoto Y., et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation 92 (1995) 1558-1564
2. de Lemos J.A., McGuire D.K., and Drazner M.H. B-type natriuretic peptide in cardiovascular disease. Lancet 362 (2003) 316-322
3. Abdullah S.M., Khera A., Das S.R., Stanek H.G., Canham R.M., Chung A.K., Morrow D.A., Drazner M.H., McGuire D.K., and de Lemos J.A. Relation of coronary atherosclerosis determined by electron beam computed tomography and plasma levels of N-terminal pro-brain natriuretic peptide in a multiethnic population-based sample (the Dallas Heart Study). Am J Cardiol 96 (2005) 1284-1289
4. Kragelund C., Gronning B., Omland T., Køber L., Strande S., Steffensen R., and Hildebrandt P. Is N-terminal pro B-type natriuretic peptide (NT-proBNP) a useful screening test for angiographic findings in patients with stable coronary disease?. Am Heart J 151 (2006) e711-e712 e717
5. Talwar S., Squire I.B., Downie P.F., Davies J.E., and Ng L.L. Plasma N terminal pro-brain natriuretic peptide and cardiotrophin 1 are raised in unstable angina. Heart 84 (2000) 421-424
6. Morita E., Yasue H., Yoshimura M., Ogawa H., Jougasaki M., Matsumura T., Mukoyama M., and Nakao K. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 88 (1993) 82-91
7. Jernberg T., Stridsberg M., Venge P., and Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 40 (2002) 437-445
8. Richards A.M., Nicholls M.G., Yandle T.G., Frampton C., Espiner E.A., Turner J.G., Buttimore R.C., Lainchbury J.G., Elliott J.M., Ikram H., Crozier I.G., and Smyth D.W. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 97 (1998) 1921-1929
9. Kikuta K., Yasue H., Yoshimura M., Morita E., Sumida H., Kato H., Kugiyama K., Ogawa H., Okumura K., Ogawa Y., and Nakao K. Increased plasma levels of B-type natriuretic peptide in patients with unstable angina. Am Heart J 132 (1996) 101-107
10. Omland T., de Lemos J.A., Morrow D.A., Antman E.M., Cannon C.P., Hall C., and Braunwald E. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol 89 (2002) 463-465
11. Omland T., Persson A., Ng L., O'Brien R., Karlsson T., Herlitz J., Hartford M., and Caidahl K. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 106 (2002) 2913-2918
12. James S.K., Lindahl B., Siegbahn A., Stridsberg M., Venge P., Armstrong P., Barnathan E.S., Califf R., Topol E.J., Simoons M.L., and Wallentin L. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 108 (2003) 275-281
13. Galvani M., Ottani F., Oltrona L., Ardissino D., Gensini G.F., Maggioni A.P., Mannucci P.M., Mininni N., Prando M.D., Tubaro M., Vernocchi A., Vecchio C., Italian Working Group on Atherosclerosis, Thrombosis, and and Vascular Biology and the Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO). N-terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes. Circulation 110 (2004) 128-134
14. Heeschen C., Hamm C.W., Mitrovic V., Lantelme N.H., White H.D., and Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 110 (2004) 3206-3212
15. Lindahl B., Lindback J., Jernberg T., Johnston N., Stridsberg M., Venge P., and Wallentin L. Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy. J Am Coll Cardiol 45 (2005) 533-541
16. Jernberg T., Lindahl B., Siegbahn A., Andren B., Frostfeldt G., Lagerqvist B., Stridsberg M., Venge P., and Wallentin L. N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. J Am Coll Cardiol 42 (2003) 1909-1916
17. James S.K., Lindback J., Tilly J., Siegbahn A., Venge P., Armstrong P., Califf R., Simoons M., Wallentin L., and Lindahl B. Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy. J Am Coll Cardiol 48 (2006) 1146-1154
18. Morrow D.A., de Lemos J.A., Sabatine M.S., Murphy S.A., Demopoulos L.A., DiBattiste P.M., McCabe C.H., Gibson C.M., Cannon C.P., and Braunwald E. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 41 (2003) 1264-1272
19. Kragelund C., Gronning B., Kober L., Hildebrandt P., and Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 352 (2005) 666-675
20. Bibbins-Domingo K., Gupta R., Na B., Wu A.H., Schiller N.B., and Whooley M.A. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA 297 (2007) 169-176
21. Tang W.H., Steinhubl S.R., Van Lente F., McErlean B.E., Maroo A., Francis G., and Topol E. Risk stratification for patients undergoing nonurgent percutaneous coronary intervention using N-terminal pro-B-type natriuretic peptide: a Clopidogrel for the Reduction of Events During Observation (CREDO) substudy. Am Heart J 153 (2007) 36-41
22. Omland T., Sabatine M.S., Jablonski K.A., Rice M.M., Hsia J., Wergeland M.T., Landaas S., Rouleau J.L., Domanski M.J., Hall C., Pfeffer M.A., Braunwald E., and PEACE Investigators. Prognostic value of B-type natriuretic peptides in patients with stable coronary disease. The PEACE Trial. J Am Coll Cardiol 50 (2007) 205-214
23. Richards M., Nicholls M.G., Espiner E.A., Lainchbury J., Troughton R., Elliott J., Frampton C., Crozier I., Yandle T., and Doughty R. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. J Am Coll Cardiol 47 (2006) 52-60